Logo
x

Search category

Subscribe Now

All Posts by Date

Insights+ Key Biosimilars Events of March 2022

Insights+ Key Biosimilars Events of March 2022

Intas Reports Results of Razumab (biosimilar, ranibizumab) in the Real-world Study for the Treatment of Diabetic Macular Edema in India

Intas Reports Results of Razumab (biosimilar, ranibizumab) in the Real-world Study for the Treatment of Diabetic Macular Edema in...

Pfizer to Acquire ReViral for ~$525M

Pfizer to Acquire ReViral for ~$525M

Pregene Signs an Exclusive License Agreement with CellPoint to Develop and Commercialize PRG-1801 for the Treatment of R/R Multiple Myeloma

Pregene Signs an Exclusive License Agreement with CellPoint to Develop and Commercialize PRG-1801 for the Treatment of R/R Multipl...

Regeneron and Sanofi’s Dupixent (dupilumab) Receive EC’s Approval for Children with Severe Asthma with Type 2 Inflammation

Regeneron and Sanofi’s Dupixent (dupilumab) Receive EC’s Approval for Children with Severe Asthma with Type 2 Inflammation

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Sch...

Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.